SPY
753.18
+0.07%
QQQ
677.07
−0.34%
BTC/USD
74,253.39
−1.33%
DIA
525.13
+0.34%
GLD
373.32
−1.64%
TLT
81.92
−0.05%
Try
Free
US
Sign in
Register
My Account
Benzinga
Premium Services
Services
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Sanofi SA
SNY
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$48.12
1.08
2.3%
Last update: Nov 10, 5:46 AM
Get Report
Overview
News
Earnings Forecast
Events
Price Targets
Financials
Sentiment
Ownership
Dividends
Compare
Options
Stock Report
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Sanofi Financials
Sanofi (SNY) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Regeneron Eyes One of Its Strongest Years Ever, Stock Jumps
Regeneron stock hits a 52-week high as earnings surge 70%, revenue jumps 36% and key drugs deliver record sales.
Vandana Singh
Dupixent Is Still Booming. Sanofi’s CEO Is Already Planning for Life Without It
Sanofi beats Q3 earnings consensus on Dupixent growth, raises 2026 guidance, and outlines long-term plans to handle upcoming patent expirations.
Vandana Singh
PRO
Sanofi Q3 Adj. EPS $2.04 Beats $1.63 Estimate, Sales $16.623B Beat $15.230B Estimate
Sanofi (NASDAQ:SNY) reported quarterly earnings of $2.04 per share which beat the analyst consensus estimate of $1.63 by 25.15 percent. This is a 22.16 percent increase over earnings of $1.67 per share from the same
Benzinga Newsdesk
PRO
Sanofi Q3 Dupixent Sales €5.7B, Up 34.8%; Vaccines Sales €3.2B, Down 6.6%
Benzinga Newsdesk
PRO
Sanofi Raises FY26 Guidance: Sees Sales Growth Low-Teens % At CER, Business EPS Growth Mid-Teens %
Benzinga Newsdesk
PRO
Sanofi Q3 Business EPS €3.55, Up 22%; Sales €14.44B, Up 16.2%, Up 14.3% At CER
Benzinga Newsdesk
